The startup operates a phenotypic screening platform that utilizes oncolytic viruses to develop targeted cancer therapies for intravenous delivery. This approach enables the identification of effective treatment candidates tailored to specific patient populations, enhancing the efficacy of cancer care.
Funding
$46.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
IUFounders
Product
Problem
Current cancer therapies often lack the specificity needed to target cancer cells effectively, leading to off-target effects and limited efficacy, particularly in complex tumor microenvironments. Existing oncolytic viral therapies have not fully explored the potential of intravenous delivery and optimization for specific patient populations. This results in a need for more targeted and effective cancer treatments that can overcome immunosuppressive tumor environments.
Solution
Theolytics is developing a new generation of oncolytic viral therapies through its phenotypic screening platform, which identifies targeted candidates optimized for intravenous delivery and specific patient populations. The company's approach leverages a library of adenovirus variants to discover therapies that selectively kill cancer cells and cancer-supporting cells while also stimulating the body's immune system to clear tumors. The platform enables the identification of therapies with enhanced clinical efficacy, safe and targeted administration, and improved manufacturing yield and stability. Theolytics' lead program focuses on developing a transformative therapy for ovarian cancer, addressing the immunosuppressive tumor environment and complex nature of the disease.
Target Audience
The primary target audience includes biopharmaceutical companies seeking strategic partnerships to expand and accelerate their pipeline development, as well as patients with advanced-stage cancers, particularly ovarian cancer, who are in need of more effective treatment options.
Features
- Proprietary discovery platforms leveraging systematic phenotypic screening technologies
- Oncolytic virus programs spanning both solid and liquid tumors
- Advanced bioselection and screening systems for identifying therapies with improved efficacy and safety
- Focus on intravenous delivery for systemic treatment
- Lead program targeting ovarian cancer with a mechanistically novel oncolytic immunotherapy (THEO-260)
- A library of 100 million adenovirus variants to identify optimized therapies